Similar articles

• Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.

  Hinderliter AL, Willis PW 4th, Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Koch G, Li S, Clayton LM, Jöbsis MM, Blackburn SD Jr, Crow JW, Long WA. Hinderliter AL, et al. Circulation. 1997 Mar 18;95(6):1479-86. doi: 10.1161/01.cir.95.6.1479. Circulation. 1997. PMID: 9118516 Clinical Trial.
• Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients.

  Nath J, Demarco T, Hourigan L, Heidenreich PA, Foster E. Nath J, et al. Echocardiography. 2005 May;22(5):374-9. doi: 10.1111/j.1540-8175.2005.04022.x. Echocardiography. 2005. PMID: 15901287
• How prostacyclin therapy improves right ventricular function in pulmonary arterial hypertension.

  Vanderpool RR, Desai AA, Knapp SM, Simon MA, Abidov A, Yuan JX, Garcia JGN, Hansen LM, Knoper SR, Naeije R, Rischard FP. Vanderpool RR, et al. Eur Respir J. 2017 Aug 24;50(2):1700764. doi: 10.1183/13993003.00764-2017. Print 2017 Aug. Eur Respir J. 2017. PMID: 28838981 Free PMC article. No abstract available.
• Managing patients with primary pulmonary hypertension: prostacyclin therapy.

  Albert NM, Hague K. Albert NM, et al. Am J Crit Care. 1997 Jul;6(4):274-80. Am J Crit Care. 1997. PMID: 9215424 Review. No abstract available.
• [Treatment of pulmonary artery hypertension].

  Olschewski H, Seeger W. Olschewski H, et al. Pneumologie. 2000 Jun;54(6):222-4. doi: 10.1055/s-2000-3823. Pneumologie. 2000. PMID: 10934891 Review. German. No abstract available.